SIGA Technologies Inc
NASDAQ:SIGA

Watchlist Manager
SIGA Technologies Inc Logo
SIGA Technologies Inc
NASDAQ:SIGA
Watchlist
Price: 5.91 USD -1.99% Market Closed
Market Cap: 421.8m USD
Have any thoughts about
SIGA Technologies Inc?
Write Note

SIGA Technologies Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SIGA Technologies Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
SIGA Technologies Inc
NASDAQ:SIGA
Income from Continuing Operations
$85.7m
CAGR 3-Years
73%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Income from Continuing Operations
$14.8B
CAGR 3-Years
-6%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Income from Continuing Operations
-$7.2B
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Income from Continuing Operations
$4.3B
CAGR 3-Years
-40%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Merck & Co Inc
NYSE:MRK
Income from Continuing Operations
$12.2B
CAGR 3-Years
27%
CAGR 5-Years
5%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Income from Continuing Operations
$8.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
12%
No Stocks Found

SIGA Technologies Inc
Glance View

Market Cap
421.8m USD
Industry
Pharmaceuticals

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
13.95 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is SIGA Technologies Inc's Income from Continuing Operations?
Income from Continuing Operations
85.7m USD

Based on the financial report for Sep 30, 2024, SIGA Technologies Inc's Income from Continuing Operations amounts to 85.7m USD.

What is SIGA Technologies Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
12%

The average annual Income from Continuing Operations growth rates for SIGA Technologies Inc have been 73% over the past three years , 12% over the past five years .

Back to Top